Category Archives: pricing
By Ben Comer | Published: November 25, 2013
FDA’s new Breakthrough Therapies designation sped Pharmacyclics/J&J’s ibrutinib (brand name: Imbruvica) through regulatory review in four months, based on Phase 2 studies. Pricing and access issues, though, may not get resolved so quickly.
By Julian Upton | Published: November 15, 2013
No More Mr NICE Guy: Pharma Takes On the UK’s Drug Watchdog In a joint letter to The Telegraph yesterday, nine of the world’s biggest pharm companies accused the UK’s drug pricing body, the National Institute for Health and Care Excellence (NICE), of blocking too many new and innovative medicines The open letter — signed by representatives [...]
By Clark Herman | Published: November 12, 2013
At last week’s Partnering for Cures conference held in New York City, several expert panels discussed new angles of approaching solutions to disease, encouraging investment and mitigating inefficiencies in the delivery of medicines within the current healthcare system. A highlight was a session on “Reimbursement: Can Value Drive Innovation?,” which looked at defining value in [...]
By Ben Comer | Published: November 7, 2013
Orphan drugs were given short shrift in PharmExec’s 2014 Pipeline Report, but a couple of pipeline candidates targeting small populations did make the list, and are expected to earn big dollars in the next few years. In the US, private and government payers haven’t yet had the nerve to balk at rare disease drug prices. [...]
By Guest Blogger | Published: November 6, 2013
By Leela Barham. Long awaited details have been announced in the Heads of Agreement for the latest Pharmaceutical Price Regulation Scheme (PPRS). It’s worth a read in full (and you can find it here) but some highlights are set out here.